MORGAN PETERS: Open Payments
NPI 1104396910 · N CHARLESTON, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,897 in 82 payments from 19 companies in 2025. Trend: 2023 $1,264 · 2024 $1,577 · 2025 $1,897
Food & beverage: $1,791Education: $106
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 13 | $467 |
| AstraZeneca Pharmaceuticals LP | 12 | $258 |
| GlaxoSmithKline, LLC. | 12 | $237 |
| Novartis Pharmaceuticals Corporation | 11 | $211 |
| Amgen Inc. | 14 | $207 |
| Genentech USA, Inc. | 5 | $123 |
| Regeneron Healthcare Solutions, Inc. | 2 | $77 |
| SANOFI-AVENTIS U.S. LLC | 1 | $72 |
| LEO Pharma Inc. | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
Products named: DUPIXENT, TEZSPIRE, FASENRA, Xolair, TRELEGY ELLIPTA, NUCALA, Rhapsido, AIRSUPRA.
Industry payments across SC — which companies pay providers there.
